Literature DB >> 27590122

Survival of Primary Penetrating Keratoplasty in Children.

Remzi Karadag1, Tommy C Y Chan2, Amir A Azari3, Parveen K Nagra3, Kristin M Hammersmith3, Christopher J Rapuano3.   

Abstract

PURPOSE: To review the indications and outcomes of children undergoing primary penetrating keratoplasty and identify prognostic factors for graft survival.
DESIGN: Retrospective, interventional case series.
METHODS: Medical records of every child 12 years of age or younger who underwent primary penetrating keratoplasty at Wills Eye Hospital Cornea Service between 2007 and 2015 were reviewed. Survival of the primary graft was analyzed using the Kaplan-Meier survival method.
RESULTS: Forty-six eyes of 35 children underwent primary keratoplasty during the study period. The mean age at the time of primary keratoplasty was 24.6 ± 39.9 months. The mean follow-up duration was 36.4 ± 28.8 months. Congenital opacity was the most common diagnosis for primary keratoplasty (89.1%). The overall mean graft survival time was 45.2 ± 5.8 months, with a survival rate of 75.7% at 1 year. The 1-year graft survival rate was 51.9% and 90.7% in eyes with and without glaucoma, respectively. Cox proportional hazards regression analysis demonstrated that the presence of glaucoma (P = .014) and concurrent operation during primary keratoplasty (P = .049) were independent prognostic factors for poor graft survival. On the other hand, age of primary keratoplasty (P = .626) and operation before or after primary keratoplasty (P = .800 and P = .104, respectively) were not associated with poorer graft survival. Half of our patients were able to achieve ambulatory vision at the last follow-up.
CONCLUSION: Although pediatric penetrating keratoplasty is challenging, successful transplantation with good graft survival can be obtained. Better understanding of prognostic factors can possibly improve graft survival in the future.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27590122     DOI: 10.1016/j.ajo.2016.08.031

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Combined Corneal Transplant, Glaucoma Drainage Implantation, and Pars Plana Vitrectomy Outcomes in a Pediatric Population.

Authors:  Kelley J Bohm; Alvaro Fernandez-Vega; Luis Acaba-Berrocal; R V Paul Chan; M Soledad Cortina
Journal:  Cornea       Date:  2022-02-05       Impact factor: 3.152

2.  Keratolenticular adhesion removal for type 2 Peters anomaly: a case report.

Authors:  Zhangliang Li; Rui Zou; Yune Zhao
Journal:  Eye Vis (Lond)       Date:  2020-07-15

3.  Surgical approach in type II Peters anomaly - case report.

Authors:  Cătălina-Ioana Tătaru; Călin Petru Tătaru; Laura Denisa Preoteasa
Journal:  Rom J Ophthalmol       Date:  2022 Jan-Mar

4.  Penetrating keratoplasty in children under 3 years old with congenital corneal opacities.

Authors:  Made Susiyanti; Burhana Mawarasti; Florence M Manurung
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

5.  Indications and outcomes of pediatric keratoplasty in a tertiary eye care center: A retrospective review.

Authors:  Rosario Gulias-Cañizo; Roberto Gonzalez-Salinas; Luis Fernando Hernandez-Zimbron; Everardo Hernandez-Quintela; Valeria Sanchez-Huerta
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

6.  Clinical features and outcome of corneal opacity associated with congenital glaucoma.

Authors:  Yu Jeong Kim; Jin Wook Jeoung; Mee Kum Kim; Ki Ho Park; Young Suk Yu; Joo Youn Oh
Journal:  BMC Ophthalmol       Date:  2018-08-02       Impact factor: 2.209

7.  Selective endothelial removal: A case series of a phase I/II surgical trial with long-term follow up.

Authors:  Yu-Chi Liu; Yu Qiang Soh; Viridiana Kocaba; Jodhbir S Mehta
Journal:  Front Med (Lausanne)       Date:  2022-07-29

8.  Histopathological examination of congenital corneal staphyloma and prognosis after penetrating keratoplasty.

Authors:  Yu Wan; Gege Xiao; Ting Yu; Pei Zhang; Jing Hong
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.